Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894525790> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2894525790 endingPage "174" @default.
- W2894525790 startingPage "168" @default.
- W2894525790 abstract "Background Safety, efficacy, and time to onset of effect of botulinum toxin type A is of importance to persons who seek improvement in glabellar frown lines, but this has not been well studied. The aim of this study was to determine the safety, efficacy, and onset of action of a newly developed botulinum toxin type A (Nabota) for the treatment of glabellar frown lines. Methods This was a single-arm, open-label, and phase 4 clinical study. Forty-two subjects with glabellar lines were treated with five times of intramuscular injection of 0.1 mL (4 U/0.1 mL) for a total of 20 U of Nabota. Efficacy and safety were assessed at 2, 3, 4, 5, and 14 days. Efficacy was assessed by the investigator and it was defined as a 1-point change on a 4-point scale. Results Improvement in glabellar frown lines at maximum frown was observed in 85.4% of subjects 2 days after administration. Improvement in glabellar lines at rest was observed in 51.2% of subjects 2 days after administration, and the proportion of subjects showing improvement increased with time. No severe adverse events were recorded. Conclusion Onset of action was observed in the majority of subjects by 2 days after administration of Nabota. In addition, Nabota was found to be safe and effective for the treatment of glabellar frown lines. Keywords: Botulinum toxins, type A / Glabellar frown line / Safety / Efficacy / Onset" @default.
- W2894525790 created "2018-10-05" @default.
- W2894525790 creator A5035095917 @default.
- W2894525790 creator A5054583041 @default.
- W2894525790 creator A5071476232 @default.
- W2894525790 creator A5091552260 @default.
- W2894525790 date "2018-09-20" @default.
- W2894525790 modified "2023-10-09" @default.
- W2894525790 title "Safety, efficacy, and onset of a novel botulinum toxin type A (Nabota) for the treatment of glabellar frown lines: a single-arm, prospective, phase 4 clinical study" @default.
- W2894525790 cites W1151031005 @default.
- W2894525790 cites W1973788946 @default.
- W2894525790 cites W1978910356 @default.
- W2894525790 cites W1980886601 @default.
- W2894525790 cites W2010307071 @default.
- W2894525790 cites W2017012921 @default.
- W2894525790 cites W2022884714 @default.
- W2894525790 cites W2030907440 @default.
- W2894525790 cites W2045314994 @default.
- W2894525790 cites W2081634193 @default.
- W2894525790 cites W2084143505 @default.
- W2894525790 cites W2087276058 @default.
- W2894525790 cites W2153351740 @default.
- W2894525790 cites W43666815 @default.
- W2894525790 doi "https://doi.org/10.7181/acfs.2018.01886" @default.
- W2894525790 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6177673" @default.
- W2894525790 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30282425" @default.
- W2894525790 hasPublicationYear "2018" @default.
- W2894525790 type Work @default.
- W2894525790 sameAs 2894525790 @default.
- W2894525790 citedByCount "8" @default.
- W2894525790 countsByYear W28945257902020 @default.
- W2894525790 countsByYear W28945257902021 @default.
- W2894525790 countsByYear W28945257902022 @default.
- W2894525790 countsByYear W28945257902023 @default.
- W2894525790 crossrefType "journal-article" @default.
- W2894525790 hasAuthorship W2894525790A5035095917 @default.
- W2894525790 hasAuthorship W2894525790A5054583041 @default.
- W2894525790 hasAuthorship W2894525790A5071476232 @default.
- W2894525790 hasAuthorship W2894525790A5091552260 @default.
- W2894525790 hasBestOaLocation W28945257901 @default.
- W2894525790 hasConcept C126322002 @default.
- W2894525790 hasConcept C141071460 @default.
- W2894525790 hasConcept C16005928 @default.
- W2894525790 hasConcept C197934379 @default.
- W2894525790 hasConcept C2777478456 @default.
- W2894525790 hasConcept C2992053201 @default.
- W2894525790 hasConcept C3018359032 @default.
- W2894525790 hasConcept C46821324 @default.
- W2894525790 hasConcept C71924100 @default.
- W2894525790 hasConceptScore W2894525790C126322002 @default.
- W2894525790 hasConceptScore W2894525790C141071460 @default.
- W2894525790 hasConceptScore W2894525790C16005928 @default.
- W2894525790 hasConceptScore W2894525790C197934379 @default.
- W2894525790 hasConceptScore W2894525790C2777478456 @default.
- W2894525790 hasConceptScore W2894525790C2992053201 @default.
- W2894525790 hasConceptScore W2894525790C3018359032 @default.
- W2894525790 hasConceptScore W2894525790C46821324 @default.
- W2894525790 hasConceptScore W2894525790C71924100 @default.
- W2894525790 hasFunder F4320322657 @default.
- W2894525790 hasIssue "3" @default.
- W2894525790 hasLocation W28945257901 @default.
- W2894525790 hasLocation W28945257902 @default.
- W2894525790 hasLocation W28945257903 @default.
- W2894525790 hasLocation W28945257904 @default.
- W2894525790 hasOpenAccess W2894525790 @default.
- W2894525790 hasPrimaryLocation W28945257901 @default.
- W2894525790 hasRelatedWork W1881852812 @default.
- W2894525790 hasRelatedWork W2151131305 @default.
- W2894525790 hasRelatedWork W2355125406 @default.
- W2894525790 hasRelatedWork W2473788747 @default.
- W2894525790 hasRelatedWork W2977368346 @default.
- W2894525790 hasRelatedWork W3014700999 @default.
- W2894525790 hasRelatedWork W3125808780 @default.
- W2894525790 hasRelatedWork W3158646832 @default.
- W2894525790 hasRelatedWork W3184902544 @default.
- W2894525790 hasRelatedWork W2523721168 @default.
- W2894525790 hasVolume "19" @default.
- W2894525790 isParatext "false" @default.
- W2894525790 isRetracted "false" @default.
- W2894525790 magId "2894525790" @default.
- W2894525790 workType "article" @default.